Paraoxonase, something more than an enzyme?;Paraoxonasa, ¿algo más que una enzima?

Medicina Clinica

Volumn 121, Issue 14, 2003, Pages 537-548

  Canales, Amaia ^a   Sánchez Muniz, Francisco J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Diet; Genetic; HDL; LDL; Paraoxonase; Peroxidation; Pharmacoterapy

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

CAUSE OF DEATH; DIET THERAPY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME MECHANISM; GENETIC PROCEDURES; HUMAN; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; PROTEIN FUNCTION; REVIEW;

EID: 0242389530     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13053392     Document Type: Review

References (128)

1. Instituto Nacional de Estadística. Defunciones según la causa de muerte. Marzo 2003. Disponible en: http://www.ine.es
2. American Heart Association: 2000 heart and stroke statistical update. Dallas: American Hearth Association, 2000; p. 1-10.
3. Saénz de la Calzada C. Fisiopatología de la isquemia miacárdica y sus consecuencias. En: Sáenz de la Calzada C, Zarco P, editores. Cardiopatía isquémica. Barcelona: Doyma S.A., 1985; p. 69-83.
4. Castrillo JM. Factores de riesgo de enfermedad vascular. En: De Oya M. director. Metabolismo lipídico. Investigación en Biomedicina. Madrid: I. M. & C., 1994; p. 39-47.
5. Schaefer EJ. 2001 lipoproteins, nutrition, and heart disease. Proceeding of Increasing High Density Lipoproteins: The Next Frontier in Heart Disease Reduction? Seminars in Atherosclerosis at Tufts University; March 30. Boston, 2001: p. 1-56.
6. Jover E. El tabaco como factor de riesgo cardiovascular. Drugs of Today 1988;24(Suppl 1):151-5.
7. Zevin S, Saunders S, Gourlay SG, Jacob P, Benowitz NL. Cardiovascular effects of carbon monoxide and cigarette smoking. J Am Coll Cardiol 2001;38:1633-8.
8. Smith CJ, Fischer TH. Particulate and vapor phase constituents of cigarette mainstream and risk of myocardial infarction. Atherosclerosis 2001;158:257-67.
9. Cuesta C, Sánchez-Muniz FJ, García-La Cuesta A, Garrido R, Castro A, San Félix B, et al. Effects of age and cigarette smoking on serum concentrations of lipids and apolipoproteins in a male military population. Atherosclerosis 1989;80:33-9.
10. o 01-3305, May 2001.
11. González-Gross M, Sola R, Castillo MJ. Folato: una vitamina en constante evolución. Med Clin (Barc) 2002;119:627-35.
12. Esterbauer H, Gebicki J, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modifications of LDL. Free Radical Biol Med 1992;13:341-90.
13. Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PW, et al. Lipoptotein (a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem 1999;45:1039-46.
14. Gotto AM Jr. High-density lipoprotein colesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002;144:S33-S42.
15. Jover E. Factores de riesgo cardiovascular en la infancia y adolescencia. En: De Oya M, Garcés C, editores. Enfermedades cardiovasculares. Nutrición, gerética y epidemiología. Madrid: Doyma S.L., 2000; p. 5-28.
16. Sehnal E, Slany J. Fibrinogen-the key to familial EC or just another shadow in Plato's allegory? Eur Heart J 2002;23:1231.
17. Parthasarathy S, Santaman N, Ramachandran S, Meilhac O. Oxidants and antioxidants in atherogenesis: an appraisal. J. Lipid Res 1999;40:2143-57.
18. Staprans I, Rapp JH, Pan XN, Feingold KR. Oxidized lipids in the diet are incorporated by the liver into very low density lipoproteins in rats. J Lipid Res 1996;37:420-30.
19. Gaziano JM, Hatta A, Flynn M, Johnson EJ, Krinsky NI, Ridker PM, et al. Supplementation with beta-carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. Atherosclerosis 1995;112:187-95.
20. Gey KF, Moser UK, Jordan P, Stahelin HB, Eichholzer M, Ludin E. Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. Am J Clin 1993;57:787S-97S.
21. Gey KF. Cardiovascular disease and vitamins. Concurrent correction of «suboptimal» plasma antioxidant levels may, as important part of «optimal» nutrition, help to prevent early stages of cardiovascular disease and cancer, respectively. Bibl Nutr Dieta 1995;52:75-91.
22. Alonso R. Vitaminas, antioxidantes. Controversias actuales. En: De Oya M. Garcés C, editores. Metabolismo lipídico. Sociedad y colesterol. Madrid: IDEPSA, 1997; p. 201-9.
23. The Heart Outcomes Preventions Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000;342:154-60.
24. Santaman N, Parthasarathy S. Paradoxical actions of antioxidants in the oxidation of low density lipoproteins by peroxidases. J Clin Invest 1995;95:2594-600.
25. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein (a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992;267:4143-51.
26. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 1993;268:11811-6.
27. Mataix J, Rodŕguez J, Quiles JL, Ochoa JJ, Battino M, López M. Aceite de oliva y estado oxidativo celular. En: Mataix J, editor. Aceite de oliva virgen: nuestro patrimonio alimentario (vol. 2). Granada: Universidad de Granada y Puleva Food, 2001; p. 37-78.
28. Gil A, Ramírez MC, Aguilera CM, Mataix J. Aceite de oliva y sistema cardiovascular I: aterosclerosis. En: Mataix J, editor. Aceite de oliva virgen: nuestro patrimonio alimentario (vol. 2). Granada: Universidad de Granada y Puleva Food, 2001; p. 79-107.
29. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;340:115-26.
30. Bruckdorfer KR. Free radicals, lipid peroxidation and atherosclerosis. Curr Op Lipidol 1990;1:529-35.
31. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witzum JL, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997;272:13597-607.
32. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-42.
33. Witzum JL. Role of oxidized low density lipoprotein in atherogenesis. Br Heart J 1993;69:12-8
34. Parthasarathy S, Barnett J, Fong LG. High density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochem Biophys Acta 1990;1044:275-83.
35. Smith LL. Review of progress in sterol oxidations. Lipids 1996;31:453-87.
36. Dietchy JM. Dietary fatty acids and the regulation of plasma low density lipoproteins colesterol concentrations. J Nutr 1998;128:444S-8S.
37. Cuesta C, Ródenas S, Merinero MC, Rodríguez-Gil S, Sánchez-Muniz FJ. Lipoprotein profiles and serum peroxide levels of aged women consuming palmolein or oleic acid-rich sunflower oil diets. Eur J Clin Nutr 1998;52:675-83.
38. Pérez-Jiménez F, Castro P, López Miranda J, Paz-Rojas E, Blanco A, López-Segura F, et al. Circulating levels of endotelial function are modulated by dietary monounsaturated fat. Atherosclerosis 1999;145:351-8.
39. Pérez-Jiménez F, López Miranda J, Pinillos D, Velasco MJ, Castro P, Ostos M, et al. A high-MUFA and a NCEP diet decrease the insulin resistance in young healthy subjects. Circulation 1998;90:193S.
40. Salas J, López Miranda J, Jansen S, Zambrana JL, Castro P, Paniagua JA, et al. La dieta rica en grasa monoisaturada modifica beneficiosamente el metabolismo de los carbohidratos y la presión arterial. Med Clin (Barc) 1999;113:765-9.
41. Fruchart JC, De Geteire C, Delfly B, Castro GR. Apolipoprotein A-containing lipoprotein particles and reverse cholesterol transport: Evidence for connection between cholesterol efflux and atherosclerosis risk. Atherosclerosis 1994;110:S35-S9.
42. Fruchart JC, Ailhaud G. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem 1992;38:793-7.
43. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, et al. Distribution of Apo A-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2670-6.
44. De Oliveira e Silva ER, Kong M, Han Z, Starr C, Kass EN, Hank Juo SH, et al. Metabolic and genetic determinants of HDL metabolism and hepatic lipase activity in normolipidemic females. J Lipid Res 1999;40:1211-21.
45. Sánchez-Muniz FJ, Merinero MC, Rodríguez-Gil S, Ordovás JM, Ródenas S, Cuesta C. Dietary fat saturation affects apolipoprotein AII levels and HDL composition in postmenopausal women. J Nutr 2002;132:50-4.
46. Rader DJ, Castro G, Zech LA, Fruchart JC, Brewer HB Jr. In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I, A-II. J Lipid Res 1991;32:1849-59.
47. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidized low-density-lipoprotein. J Clin Invest 1995;95:774-82.
48. Forte TM, Oda MN, Knoff L, Frei B, Suh J, Harmony JA, et al. Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. Lipid Res 1999;40:1276-83.
49. Kudchodkar BJ, Lacko AG, Dory L, Fungwe TV. Dietary fat modulates serum paraoxonase 1 activity in rats. J Nutr 2000;130:2427-33.
50. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
51. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996;14:334-6.
52. Clendenning JB, Humbert R, Green ED, Word C, Traver D, Furlong CE. Structural organization of the human PON 1 gene. Genomics 1996;35:586-9.
53. Li WF, Matthews C, Disteche CM, Costa LG, Furlong CE. Paraoxonase (PON 1) gene in mice: sequencing, chromosomal localisation and development expression. Pharmacogenomics 1997;7:137-44.
54. Sorenson RC, Primo-Parmo SL, Camper SA, La Du BN. The genetic mapping and gene structure of mouse paraoxonase/arylesterase. Genomics 1995;30:431-8.
55. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci USA 1995;92:7187-91.
56. Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998;9:319-24.
57. Ozols J. Isolation and complete covalent structure of liver microsomal paraoxonase. Biochem J 1999;338:289-93.
58. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON 1) is one member of a multigene family. Genomics 1996;33:498-509.
59. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76.
60. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996;97:1630-9.
61. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic n-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999;19:2214-25.
62. Mueller RF, Horning S, Furlong CE, Anderson J, Giblett ER, Motulsky A. Plasma paraoxonase polymorphism, a new enzyme assay: population, family, biochemical and linkage studies. Am J Hum Genet 1983;35:393-408.
63. Playfer JR, Eze LC, Bullen MF, Evans DAP. Genetic polymorphism and interethnic variability of plasma paraoxonase activity. J Med Genet 1976;13:337-42.
64. Sánchez-Muniz FJ, Cuesta C, Bastida S, Perea S, Moya M. Perfil lipoproteico en una muestra seleccionada de neonatos a término del estudio Toledo. An Pediatr (Esp) 1994;40:173-80.
65. Bastida S, Sánchez-Muniz FJ, Cuesta C, Perea S, Aragonés A. Male and female cord blood lipoprotein profile differences throughout the term-period. J Perinatal Med 1997;27:184-91.
66. Calleja L, Trallero MC, Paris A, Iturralde M, Osada J. Regulación de la expresión de la apolipoproteína AI. En: De Oya M, director. Metabolismo lipídico. Investigación en Biomedicina. Madrid: I. M. & C., 1994; p. 307-15.
67. Uriel A. Characterisation descholinesterases et d'autres esterases carboxylique après electrophorese et immunoelectrophorese en gleose I: applications a l'etude des esterases dy serum humain normal. Ann Inst Pasteur 1961;101:104.
68. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein. K-85: identity of K-85 with paraoxonase. Eur J Biochem 1993;211:871-9.
69. La Du BN, Novais J. Human serum organophosphatase: biochemical characteristics and polymorphic inheritance. En: Reiner E, Aldrige WN, Hoskin FCG, editors. Enzymes hydrolysing Organophosphorus compounds. Chichester: Ellis-Horwood, 1989; p. 41-52.
70. Kuo CL, La Du BN. Comparison of purified human and rabbit serum paraoxonases. Drug Metab Dispos 1995;215:127-38.
71. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-6
72. Noto H, Hashimoto Y, Satoh H, Hara M, Iso-o N, Togo M, et al. Exclusive association of paraoxonase 1 with high-density lipoprotein particles in apolipoprotein A-I deficiency. Biophys Res Commun 2001;289:395-401.
73. Takata K, Saku K, Ohta T, Takata M, Bai H, Jimi S, et al. A new case of apo AI deficiency showing codon 8 nonsense mutation of the apo AI gene without evidence of coronary heart disease. Arterioscler Thromb Vasc Biol 1995;15:1866-74.
74. James RW, Garin MC, Calabresi L, Miccoli L, Von Eckardestein A, Tilly-Kiesi M, et al. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis 1998;139:77-82.
75. Tailleux A, Duriez P, Fruchart JC, Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 2002;164:1-13.
76. Brewer HB Jr, Lux SE, Ronan R, John KM. Amino acid sequence of human apoLp-GlnII (apo AII), an apolipoprotein isolated from the high-density lipoprotein complex. Proc Natl Acad Sci USA 1972;69:1304-8.
77. Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM. Lipoproteins alter the catalytic behaviour of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci USA 1989;86:2393-7.
78. Tselepis AD, Dentan C, Karabina SAP, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL1 in human plasma. Arterioscler Thromb Vasc Biol 1995;15:1764-73
79. Boman H. Cholinesterase, arylesterase and lipoprotein parameters in twins. Acta Genet Med Gemellol 1980;29:281-7.
80. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JAK. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994;33:832-9.
81. Choi-Miura NH, Takahashi Y, Nakano Y, Tobe T, Tomita M. Identification of the disulfide bonds in human plasma proteins SP-40, 40 (apolipoprotein-J). J Biochem (Tokyo) 1992;112:557-61.
82. Jennes DE, Lowin B, Petisch MC, Bottchert A, Schmitz G, Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein AI in human plasma. J Biol Chem 1990;266:11030-6.
83. Jordan-Starck TC, Witte DP, Aronow BJ, Harmony JAK. Apolipoprotein J: a membrane policeman? Curr Opin Lipidol 1992;3:75-85.
84. Choi-Miura NH, Ohtaki ST, Nakamura H, Isgizawa S, Takagi Y, Gomi K, et al. Elevated complement activities of sera from patients with high density lipoprotein deficiency (Tangier disease): the presence of normal level of clusterin and the posible implication in the atherosclerosis. Clin Exp Immunol 1993;93:242-7.
85. Tschopp J, French LE. Clusterin: modulation of complement function. Clin Exp Immunol 1994;97:11-4.
86. Rosenberg ME, Silkenson J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995;27:633-45.
87. Wong P, Pineault J, Lakins J, Taillefer D, Leger J, Wang C, et al. Genomic organization and expression of the rat TRMP-2 (clusterin) gene, a gene implicated in apoptosis. J Biol Chem 1993;268:5021-31.
88. French LE, Wohiwend A, Sappino AP, Tschopp J, Schifferli A. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J Clin Invest 1994;93:877-84.
89. Witte DP, Aronow BJ, Stauderman WD, Stuart MA, Clay RA, Gruppo SH, et al. Platelet activation releases megakaryocyte-synthesized apolipoprotein J, highly abundant protein in atheromatous lesions. Am J Pathol 1993;143:763-73.
90. Jordan-Starck TC, Lund SD, Witte DP, Aronow BJ, Ley CA, Stuart WD, et al. Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. J Lipid Res 1994;35:194-210.
91. Jenne DE, Lowin B, Peitsch MC, Bottcher A, Schmitz G, Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 1991;266:11030-6.
92. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, et al. Oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997;99:2005-19.
93. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;915-24.
94. Parthasarathy S. Modified lipoproteins in the pathogenesis of atherosclerosis. Austin: R. G. Landes Co., 1994; p. 91-119.
95. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
96. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35.
97. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998;18:1617-24.
98. La Du BN. Is paraoxonase-3 another HDL-associated protein protective against atherosclerosis? Arterioscler Thromb Vasc Biol 2001;21:467-8.
99. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001;21:542-7.
100. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001;276:44444-9.
101. Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizengra JJ, et al. Human PON 2 gene at 7q21. 3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998;213:149-57.
102. Humbert R, Adler DA, Distecke CM, Hassert C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6.
103. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000;149:435-42.
104. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997;17:2935-9.
105. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genetics 1996;14:334-6.
106. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, editor. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press. 1992; p. 51-91.
107. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997;99:62-6.
108. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphism of human paraoxonase (PON 1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997;112:265-8.
109. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598-608.
110. Tomás M, Senti M, García-Faria F, Vila J, Torrents A, Covas M, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000;20:2113-9.
111. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arteriocler Thromb Vasc Biol 1995;15:89-95.
112. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON 3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000;275:33435-42.
113. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991;86:193-9.
114. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1812-8.
115. Milochevitch C, Khalil A. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukot Essent Fatty Acids 2001;65:241-6.
116. Garrido JA. Manejo de la dislipidemia en ancianos y mujeres. En: De Oya M, Garcés C, editores. Enfermedades cardiovasculares. Nutrición, genética y epidemiología. Madrid: Doyma S.L., 2000; p. 71-85.
117. Duverger N, Rader D, Brewer HB. Distribution of subclasses of HDL containing apo AI without apo AII (LpA-I) in normolipidemic men and women. Arterioscler Thromb 1994;14:1594-9.
118. Beltowski J, Wojcicka G, Mydlarczyk M, Jamroz A. Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. Pol J Pharmacol 2002;54:143-50.
119. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998;138:217-25.
120. Turay J, Grniakova V, Valka J. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate. Drugs Exp Clin Res 2000;26:83-8.
121. Balogh Z, Seres I, Harangi M, Kovacs P, Kakuk G, Paragh G. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab 2001;27:604-10.
122. Kleemola P, Freese R, Jauhiainen M, Pahlman R, Alfthan G, Mutanen M. Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 2002;160:425-32.
123. Van der Gaag MS, Van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999;147:405-10.
124. Sutherland WH, Walker RJ, De Jong SA, Van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 1999;19:1340-7.
125. Mackness M, Boullier A, Hennuyer N, Mackness B, Hall M, Tailleux A, et al. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun 2000;269:232-6.
126. Hedrick CC, Hassan K, Hough GP, Yoo JH, Simzar S, Quinto CR, et al. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol 2000;20:1946-52.
127. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002;22:1329-33.
128. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000;101:2252-7.